CTRI/2022/02/040563尚未招募未知
Immunogenicity and safety study of single booster dose of CORBEVAX vaccine
Asian Healthcare Foundation0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Determined by medical history, targeted physical examination and clinical judgement of the investigator to be in good health. Note: Heathy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrolment, can be included.
- •2. Subject is willing to provide a written informed consent for voluntary participation in the study.
- •3. Subject agrees to refrain from blood donation during the course of the study.
- •4. Subject have completed at least 6 months duration after second dose of vaccination
排除标准
- •1. Pregnant women, nursing women or women of childbearing potential who are not actively avoiding pregnancy during the study.
- •2. Subjects with known current or chronic history of any of the following conditions, likely to affect participation in the study: any bleeding disorder
- •3. Subjects requiring chronic administration (defined as more than 14 days in total) of immunosuppressant (e.g., corticosteroids, cytotoxic drugs or antimetabolites, etc.) or other immune-modifying drugs (e.g., interferons).
- •4. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •5. Any medical condition that in the judgment of the investigator would make study participation unsafe.
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Immune Response after a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-004461-41-Outside-EU/EEASanofi Pasteur Inc570
进行中（未招募）
不适用
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in MexicoPrevention of symptomatic dengue diseaseEUCTR2014-001736-11-Outside-EU/EEASanofi Pasteur SA732
进行中（未招募）
不适用
Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination with Infanrix® hexa when Both Vaccines Are Co-Administered with Prevenar® to Toddlers 11-18 Months of AgePEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused by Haemophilus influenzae type b), as a booster dose administered to toddlers previously primed with three doses of a hexavalent vaccine.EUCTR2006-000898-30-DESanofi Pasteur Incorporated
尚未招募
4 期
Safety and Immunogenicity of a booster dose of inactivated Vero-cell-derived Japanese Encephalitis vaccine (JEVAC) in children whom primed with live attenuated JE vaccine.Healthy childrenJapanese encephalitisJapanese encephalitis vaccineImmunogenicityBoosterInactivated JE vaccineTCTR20190507007iaoning Cheng Biotechnology, Shenyang150
已完成
4 期
Intradermal second booster COVID-19 vaccinatioThe second booster intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2.booster vaccine, SAR-CoV2, older adult, intradermal vaccination, elderly, ThailandTCTR20230411008Faculty of Medicine Siriraj hospital, Mahidol University107